文献速递帕金森病与运动障碍

多系统萎缩与帕金森病患者皮肤α-突触核蛋白特征

Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease.
PubMed 文献 · Neurology · 2023-01-19

研究纳入31例多系统萎缩(MSA)患者、54例帕金森病(PD)患者和24名匹配对照,所有受试者接受神经科检查、自主神经测试和3处皮肤活检。结果显示MSA患者磷酸化α-突触核蛋白沉积更多且外周分布更广,区分MSA与PD的敏感度和特异度均>90%。

要点

  • MSA患者皮肤磷酸化α-突触核蛋白沉积程度和分布范围均大于PD患者(p<0.0001)。
  • 所有MSA患者和51/54例PD患者至少一处皮肤活检检出磷酸化α-突触核蛋白,对照均未检出。
  • 皮肤活检磷酸化α-突触核蛋白检测区分MSA与PD的敏感度和特异度均>90%。

核心结论

  • α-突触核蛋白存在于MSA患者外周自主神经,结合其分布特征可准确区分MSA与PD。

研究设计与样本

  • 研究纳入31例MSA患者、54例PD患者(均符合现行临床共识标准)和24名匹配对照,所有受试者接受神经科检查、自主神经测试及3处皮肤活检,测量表皮内、泌汗和竖毛神经纤维密度并量化磷酸化α-突触核蛋白沉积。

主要发现

  • PD患者神经纤维密度低于MSA患者(p<0.05,所有纤维类型)。
  • 所有MSA患者和51/54例PD患者至少一处皮肤活检检出磷酸化α-突触核蛋白,对照均未检出。
  • MSA患者磷酸化α-突触核蛋白沉积量大于PD患者(p<0.0001),外周分布范围也更广(p<0.0001)。
  • 上述结果区分MSA与PD的敏感度和特异度均>90%。

关键数值与推荐

  • 皮肤活检磷酸化α-突触核蛋白检测区分MSA与PD的敏感度和特异度均>90%。
  • 本研究提供II级证据表明皮肤活检磷酸化α-突触核蛋白测定可区分MSA与PD患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder caused by the abnormal accumulation of α-synuclein in the nervous system. Clinical features include autonomic and motor dysfunction, which overlap with those of Parkinson disease (PD), particularly at early disease stages. There is an unmet need for accurate diagnostic and prognostic biomarkers for MSA and, specifically, a critical need to distinguish MSA from other synucleinopathies, particularly PD. The purpose of the study was to develop a unique cutaneous pathologic signature of phosphorylated α-synuclein that could distinguish patients with MSA from patients with PD and healthy controls. METHODS: We studied 31 patients with MSA and 54 patients with PD diagnosed according to current clinical consensus criteria. We also included 24 matched controls. All participants underwent neurologic examinations, autonomic testing, and skin biopsies at 3 locations. The density of intraepidermal, sudomotor, and pilomotor nerve fibers was measured. The deposition of phosphorylated α-synuclein was quantified. Results were compared with clinical rating assessments and autonomic function test results. RESULTS: Patients with PD had reduced nerve fiber densities compared with patients with MSA (p < 0.05, all fiber types). All patients with MSA and 51/54 with PD had evidence of phosphorylated α-synuclein in at least one skin biopsy. No phosphorylated α-synuclein was detected in controls. Patients with MSA had greater phosphorylated α-synuclein deposition (p < 0.0001) and more widespread peripheral distribution (p < 0.0001) than patients with PD. These results provided >90% sensitivity and specificity in distinguishing between the 2 disorders. DISCUSSION: α-synuclein is present in the peripheral autonomic nerves of patients with MSA and when combined with synuclein distribution accurately distinguishes MSA from PD. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that measurement of phosphorylated α-synuclein in skin biopsies can differentiate patients with MSA from those with PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gibbons C, Wang N, Rajan S, et al. Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease. Neurology. 2023. PMID: 36657992. doi:10.1212/WNL.0000000000206772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。